Soldiers Carry 20 Pounds of Lithium Batteries?

From Investing Trends | Ad

U.S. soldiers may carry up to 20 pounds of lithium batteries! In fact, nearly every American weapon defense system requires lithium batteries.

See Who Will Benefit From This Lithium Opportunity

Stuart M. Grant Insider Information

Major Shareholder of Eyenovia

Stuart Grant is the Major Shareholder of Eyenovia.

What is Stuart M. Grant's net worth?: The estimated net worth of Stuart M. Grant is at least $9.10 million as of June 21st, 2022. Grant owns 5,084,998 shares of Eyenovia stock worth more than $9,102,146 as of June 29th. This net worth approximation does not reflect any other investments that Grant may own. Learn More about Stuart M. Grant's net worth.
How do I contact Stuart M. Grant?: The corporate mailing address for Grant and other Eyenovia executives is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. Eyenovia can also be reached via phone at (917) 289-1117 and via email at [email protected] Learn More on Stuart M. Grant's contact information.
Has Stuart M. Grant been buying or selling shares of Eyenovia?: In the last ninety days, Stuart M. Grant has bought $418,899.24 of Eyenovia stock. Most recently, 0 shares of the firm's stock in a transaction on Wednesday, June 29th. Learn More on Stuart M. Grant's trading history.
Who are Eyenovia's active insiders?: Eyenovia's insider roster includes Stuart Grant (Major Shareholder), Tsontcho Ianchulev (CEO), Kenneth Lee, Jr. (Director), Charles Mather, IV (Director), and Michael Rowe (COO). Learn More on Eyenovia's active insiders.
Are insiders buying or selling shares of Eyenovia?: In the last twelve months, Eyenovia insiders bought shares 19 times. They purchased a total of 646,334 shares worth more than $1,948,730.09. The most recent insider tranaction occured on June, 21st when Major Shareholder Stuart M Grant bought 100,000 shares worth more than $165,000.00. Insiders at Eyenovia own 20.0 % of the company. Learn More about insider trades at Eyenovia.
Information on this page was last updated on 6/21/2022.

Stuart M. Grant Insider Trading History at Eyenovia

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/21/2022	Buy	100,000	$1.65	$165,000.00	5,084,998
5/10/2022	Buy	50,000	$1.98	$99,000.00	4,959,998
5/4/2022	Buy	24,074	$2.26	$54,407.24	4,909,998
4/21/2022	Buy	38,800	$2.59	$100,492.00	4,865,924
2/22/2022	Buy	42,000	$2.75	$115,500.00
2/18/2022	Buy	10,000	$2.85	$28,500.00
2/7/2022	Buy	36,030	$2.97	$107,009.10
12/15/2021	Buy	100,000	$3.45	$345,000.00
11/15/2021	Buy	75,000	$3.64	$273,000.00
10/29/2021	Buy	15,505	$3.75	$58,143.75
10/25/2021	Buy	33,806	$4.00	$135,224.00
8/19/2021	Buy	50,000	$3.98	$199,000.00
8/17/2021	Buy	23,419	$4.00	$93,676.00
4/19/2021	Buy	30,692	$4.89	$150,083.88	4,279,748
3/5/2021	Buy	35,000	$5.50	$192,500.00	4,254,748
10/12/2020	Buy	100,000	$3.55	$355,000.00	4,169,748
9/24/2020	Buy	75,000	$2.99	$224,250.00	4,069,748
8/19/2020	Buy	333,000	$3.60	$1,198,800.00	3,593,128
3/23/2020	Buy	903,240	$2.06	$1,860,674.40
11/12/2019	Buy	29,945	$2.70	$80,851.50	2,226,183
10/30/2019	Buy	25,000	$2.85	$71,250.00	2,226,183
10/16/2019	Buy	15,000	$3.14	$47,100.00	2,226,183
10/14/2019	Buy	6,700	$3.25	$21,775.00	2,226,183
10/2/2019	Buy	5,000	$3.33	$16,650.00	2,226,183
9/30/2019	Buy	17,940	$3.70	$66,378.00	2,226,183
9/27/2019	Buy	312	$4.00	$1,248.00	2,226,183

Stuart M. Grant Buying and Selling Activity at Eyenovia

Eyenovia Company Overview

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.

Today's Range

Now: $1.79

$1.73

$1.88

50 Day Range

MA: $2.14

$1.71

$2.66

2 Week Range

Now: $1.79

$1.61

$6.63

Volume

151,733 shs

Average Volume

112,664 shs

Market Capitalization

$60.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.08

183 Pounds of Copper for Just ONE EV

From Investing Trends | Ad

To build just one electric vehicle (EV) engine requires 183 pounds of copper. Compare that to just 18 pounds required in a gas-powered car. That's 10 TIMES more copper. EVs are expected to increase 1,400% by 2030. More sources of copper are desperately needed to keep up with demand.

See Who Can Benefit from Huge Copper Demand.